Hanne Løvdal Gulseth

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

The effects of acute and chronic exercise on <scp>PGC</scp>‐1α, irisin and browning of subcutaneous adipose tissue in humans

Frode Norheim, Torgrim M. Langleite, Marit Hjorth et al. · FEBS Journal · 2013 · 560 citations · Full text

Life Sciences, Endocrinology, Physiology +17

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

Carolyn S.P. Lam, Shun Kohsaka, Avraham Karasik et al. · Journal of the American College of Cardiology · 2018 · 466 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Anton Pottegård, Lars Christian Lund, Øystein Karlstad et al. · BMJ · 2021 · 431 citations · Full text

Medicine, Hematology, Immunology +17

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Thomas R. Pieber, Bruce W. Bode, Young Min Cho et al. · The Lancet Diabetes & Endocrinology · 2019 · 274 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9